Disruptive Technology? Piramal Gets EU Nod For Regenerative Cartilage Repair Therapy
This article was originally published in PharmAsia News
Executive Summary
Indian company says its product is a cheaper, off-the-shelf option for patients with cartilage injuries of the knee.
You may also be interested in...
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes
Cartilage Repair: The Next Wave in Orthopedics
The musculoskeletal sector continues to be bogged down by the economic downturn, and particularly hard hit is the industry’s largest segment: the $13 billion total joint market. Companies are now scouting out the next technology wave in orthopedics, and the record attendance at the recent International Cartilage Repair Society meeting may be one indication of where the action will be for some time to come.
Cartilage Repair: What's the Right Combination?
START-UP counts some 40 commercial development efforts in cartilage repair and regeneration. Some are implanting synthetic scaffolds, and some are offering cell-based therapies used with or without scaffolds. It's a crowded and confusing category. So many companies are chasing a market that is still somewhat undefined and doesn't seem large enough to support them all. What's clear, however, is that almost 15 years after the introduction of Carticel, the first cell-based implant for cartilage repari, there is still an unsatisified market of patients aged 20-60 with knee pain due to cartilage damage or degeneration.